EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Population Pharmacokinetics of Valemetostat and Exposure–Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T–Cell Lymphoma

Hiroyuki Inoue, Xiaoning Wang, Ramon Garcia, Brian Reilly, Masaya Tachibana iD, YoungJun Yoo, Yvonne Lau, Yang Chen

The Journal of Clinical Pharmacology · 2025

DOI: 10.1002/jcph.70100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Hiroyuki Inoue und 7 weiteren Autor:innen. Beteiligte Einrichtung: Daiichi Sankyo Co., Ltd, Tokyo, Japan. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Peripheral, Models, Biological, Antineoplastic Agents, Benzamides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Daiichi Sankyo Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Valemetostat is a dual inhibitor of EZH2/1 approved in Japan for the treatment of relapsed/refractory (R/R) adult T–cell lymphoma/leukemia (ATLL) and R/R peripheral T–cell lymphoma (PTCL). It is administered orally once daily (QD) at 200 mg. Here, we present comprehensive population pharmacokinetic (PPK) and exposure–response (ER) analyses of valemetostat. The PPK model included data from six clinical trials in patients with non–Hodgkin lymphoma, including ATLL/PTCL, or healthy participants. ER efficacy analyses were based on data from one phase 2 clinical trial in patients with PTCL; ER safety analyses used data from three trials in patients with ATLL or PTCL. Valemetostat unbound average concentration up to event was used as the exposure metric. ER analyses included overall response rates for efficacy and six safety endpoints (any Grade ≥3 treatment–emergent adverse event [TEAE]; Grade ≥3 thrombocytopenia, anemia, and neutropenia; and dose reduction and interruption due to TEAEs). Valemetostat pharmacokinetics were well described by a three–compartment model, with a sequential linked zero–/first–order absorption, a saturable binding component in the central compartment, and linear elimination of unbound valemetostat from the central compartment. Alpha‐1‐acid glycoprotein was the only identified covariate significantly affecting total valemetostat exposure but had no impact on unbound exposure. The ER relationship on efficacy was not significant, and positive relationships were identified for multiple safety endpoints. Safety simulations across different doses suggested an acceptable safety profile for 200 mg QD. Overall, these analyses support the favorable benefit–risk profile of valemetostat at 200 mg QD in patients with R/R PTCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, T-Cell, PeripheralModels, BiologicalAntineoplastic AgentsBenzamidesHumansMaleMiddle AgedFemaleAdultAgedDose-Response Relationship, DrugTreatment OutcomeYoung Adult

Stichwörter der Autor:innen

exposure–response analysisperipheral T–cell lymphomapopulation pharmacokinetic modelingvalemetostat

Substanzen

Antineoplastic AgentsBenzamides

Autor:innen und Institutionen

  • Daiichi Sankyo Co., Ltd, Tokyo, Japan.
  • Metrum Research Group, Tariffville, CT, USA.
  • Daiichi Sankyo Inc., Basking Ridge, NJ, USA.

ORCID-Profile: Masaya Tachibana

Förderung

  • Daiichi Sankyo Company

Zitieren

APA

Inoue, H., Wang, X., Garcia, R., Reilly, B., Tachibana, M., Yoo, Y., Lau, Y., & Chen, Y. (2025). Population Pharmacokinetics of Valemetostat and Exposure–Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T–Cell Lymphoma. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70100

Vancouver

Inoue H, Wang X, Garcia R, Reilly B, Tachibana M, Yoo Y, et al. Population Pharmacokinetics of Valemetostat and Exposure–Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T–Cell Lymphoma. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.70100

BibTeX
@article{Inoue2025,
  author = {Inoue, Hiroyuki and Wang, Xiaoning and Garcia, Ramon and Reilly, Brian and Tachibana, Masaya and Yoo, YoungJun and Lau, Yvonne and Chen, Yang},
  title = {Population Pharmacokinetics of Valemetostat and Exposure–Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T–Cell Lymphoma},
  journal = {The Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/jcph.70100}
}
Kostenlos starten →